NCT04768985已完成1 期
A Phase I, Open-Label, Randomized, 2-Treatment, 2-Period, Crossover Study in Healthy Subjects to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 66
- 试验地点
- 4
- 主要终点
- Maximum observed plasma (peak) drug concentration (Cmax) of Acalabrutinib
研究概览
简要总结
This study is a multicenter, Phase I, open-label, randomized, 2-sequence, 2-treatment, 2-period, crossover, bioequivalence study with single doses of acalabrutinib administered orally in healthy participants. The study is designed to demonstrate the bioequivalence of acalabrutinib tablet (Treatment A) compared with marketed acalabrutinib capsule (Treatment B) in the fasted state.
详细描述
Eligible healthy participants will be randomized to receive either treatment sequence 1 (AB) or treatment sequence 2 (BA), as follows:
- Treatment A: Acalabrutinib tablet, 100 mg, fasted state
- Treatment B: Acalabrutinib capsule, 100 mg, fasted state
Participants will receive fixed single doses of acalabrutinib on 2 occasions, under fasted conditions.
The study will comprise:
- Visit 1: A screening period of up to 28 days before first dosing.
- Visit 2: Two treatment periods:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Females must have a negative pregnancy test at Screening and on admission to the study center, must not be lactating, and must be of non-childbearing potential, confirmed at Screening, by fulfilling protocol defined criteria
- •Have a body mass index between 18.5 and 30 kg/m^2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive, at Screening
- •Non-smokers and those participants who have not smoked (including e cigarettes) or used nicotine products (cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or any other nicotine containing products) within the 90 days prior to Screening
- •Calculated creatinine clearance (CrCl) ≥ 90 mL/min as determined by Cockcroft-Gault method (using actual body weight)
- •CrCl = Weight (kg) × (140 - Age)/72 × serum creatinine (mg/dL) in mL/min
- •CrCl = Weight (kg) × (140 - Age) × 0.85/72 × serum creatinine (mg/dL) in (mL/min)
排除标准
- •History or presence of any clinically significant disease (including active coronavirus disease 2019 [COVID-19] infection) or disorder
- •History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
- •Any clinically significant illness, medical/surgical procedure, or trauma within 30 days of the first administration of study drug
- •Any clinically significant abnormalities in hematology, coagulation, clinical chemistry, or urinalysis results, at Screening and prior to first dose, as judged by the Investigator and defined as:
- •(i) Hemoglobin less than lower limit of normal (ii) Absolute neutrophils less than lower limit of normal (iii) Platelets less than lower limit of normal (iv) Serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase or serum bilirubin (total bilirubin and direct bilirubin) > upper limit of normal
- •Any clinically significant abnormal findings in vital signs at Screening or on Day 1 (eg, systolic BP < 90 mmHg or > 140 mmHg; diastolic BP < 50 mmHg or > 90 mmHg; pulse < 45 or > 90 bpm)
- •Any clinically significant abnormalities on standard 12-lead ECG at Screening or on Day 1
- •Any positive result for HBsAg, hepatitis C antibody, and HIV testing, at Screening
- •Has received a new chemical entity (defined as a compound which has not been approved for marketing) within 90 days of the first administration of study drug in this study. The period of exclusion begins 90 days after the final dose or 30 days after the last visit whichever is the longest
- •History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to acalabrutinib
- •Positive screen for drugs of abuse or cotinine and alcohol, at Screening and on admission to the study center
- •Treatment with prescription or non-prescription drugs or other products known to be strong CYP3A, P-gp, or breast cancer resistance protein (BCRP) inhibitors or substrates of BCRP or MATE1 (within 14 days before first administration of study drug or longer if the medication has a long half life) and strong CYP3A inducers (within 28 days before first administration of study drug or longer if the medication has a long half life)
- •Use of any prescribed or non prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose), and minerals during the 14 days prior to the first administration of study drug or longer if the medication has a long half life
- •Excessive intake of caffeine-containing drinks or food (eg, coffee, tea, chocolate) as judged by the Investigator
- •Inability to swallow acalabrutinib tablets or acalabrutinib capsules
- •Evidence of ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections)
- •Participant has a positive test result for severe acute respiratory syndrome coronavirus 2 reverse transcriptase polymerase chain reaction before randomization
- •Participant has clinical signs and symptoms consistent with COVID-19, eg, fever, dry cough, dyspnea, sore throat, fatigue, or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening or on admission
- •History of severe COVID-19 (hospitalization, extracorporeal membrane oxygenation, mechanically ventilated)
- •Participants who are regularly exposed to COVID-19 as part of their daily life (eg, health care professionals working in COVID-19 wards or at emergency departments)
结局指标
主要结局
Maximum observed plasma (peak) drug concentration (Cmax) of Acalabrutinib
时间窗: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
To compare the Cmax of acalabrutinib capsule with the tablet
Area under plasma concentration time curve from zero to infinity (AUCinf) of Acalabrutinib
时间窗: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
To compare the AUCinf of acalabrutinib capsule with the tablet.
Area under the plasma concentration time curve from zero to the last quantifiable concentration (AUClast) of Acalabrutinib
时间窗: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose
To compare the AUClast of acalabrutinib capsule with the tablet.
次要结局
- Area under plasma concentration time curve from zero to infinity (AUCinf) of ACP-5862(Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose)
- Area under the plasma concentration time curve from zero to the last quantifiable concentration (AUClast) of ACP-5862(Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose)
- Maximum observed plasma (peak) drug concentration (Cmax) of ACP-5862(Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose)
- Time to reach peak or maximum concentration (tmax) following drug administration for acalabrutinib and ACP-5862(Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose)
- Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t½λz) for acalabrutinib and ACP-5862(Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose)
- Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRT) for acalabrutinib and ACP-5862(Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose)
- Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz) for acalabrutinib and ACP-5862(Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose)
- Metabolite (ACP-5862) to parent (acalabrutinib) ratio based on AUCinf and/or AUClast (M:P[AUC])(Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose)
- Metabolite (ACP-5862) to parent (acalabrutinib) ratio based on Cmax (M:P [Cmax])(Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours post-dose)
- Number of participants with adverse events and serious adverse events(From screening day (Day -28) until Follow-up/end of treatment visit (at 7 to 10 days after last study drug administration))
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady StateMetastatic Melanoma, BRAF V600 Mutation PositiveNCT02608034Genentech, Inc.32
已完成
1 期
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesHematological NeoplasmsNon-Hodgkin's LymphomaHodgkin's LymphomaMyelodysplastic SyndromesNeoplasmsMultiple MyelomaLymphomaLeukemiaMelanomaOsteosarcomaGenitourinaryBreast CancerNon-Small Cell Lung CancerMetastatic Breast CancerSarcomaRenal Cell CarcinomaAcute Myeloid LeukemiaSmall Cell Lung CancerThyroid CancerGlioblastoma MultiformeNCT02223052Celgene89
已完成
1 期
A Study to Assess the Effect of Plazomicin on the Pharmacokinetics of MetforminHealthy VolunteersNCT03270553Achaogen, Inc.16
终止
1 期
A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)CancerNCT02235740Novartis1
尚未招募
2 期
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast CancerEarly Breast CancerNCT04659499Peking Union Medical College Hospital261